扩散加权成像和临床分期在鼻咽癌预后评估中的价值
作者:
基金项目:

国家自然科学基金资助项目(81871410)


The values of diffusion-weighted imaging and clinical staging in the prognostic evaluation of nasopharyngeal carcinoma
Author:
  • 摘要
  • | |
  • 访问统计
  • | |
  • 相似文献
  • | |
    摘要:

    目的探讨扩散加权成像(DWI)测量的表观扩散系数值(ADC)和鼻咽癌2017分期在预后评估中的价值。方法回顾性分析90例鼻咽癌患者的临床和影像资料,评估原发肿瘤ADC值与鼻咽癌分期的相关性。治疗后进行随访,患者的中位随访时间为54个月(5~90个月),根据疾病进展情况分为疾病进展组(29例)和非进展组(61例),探讨影响鼻咽癌预后的因素。结果Ⅰ、Ⅱ期患者原发肿瘤ADC值显著高于Ⅲ期和Ⅳa期患者(P<0.05)。T1、T2期患者原发肿瘤ADC值显著高于T4期患者(P<0.05)。多因素分析显示,Ⅳa期较Ⅰ~Ⅲ期发生疾病进展的风险更大(OR=3.497,P=0.001)。结论鼻咽癌原发肿瘤ADC值与我国鼻咽癌2017分期相关。临床分期是鼻咽癌预后的预测因子。

    Abstract:

    ObjectiveTo explore the values of the apparent diffusion coefficient (ADC) measured by diffusion-weighted imaging and the 2017 staging system of nasopharyngeal carcinoma in the prognostic evaluation.MethodsClinical and imaging data of 90 nasopharyngeal carcinoma patients were retrospectively analyzed. The correlation between ADC values of primary tumor and T stages, N stages and clinical stages were evaluated. The median follow-up time was 54 months (5 to 90 months). According to the disease progression after chemoradiotherapy, they were divided into progressive group(29 cases) and non-progressive group(61 cases).ResultsThe ADC values of primary tumor of Ⅰ and Ⅱ stages were significantly higher than those of Ⅲ and IVa stages (P < 0.05). The ADC values of T1 and T2 stages were significantly higher than that of T4 stage(P < 0.05). Multivariate analysis showed that the risk of disease progression in Ⅳa stage was higher than those in Ⅰ to Ⅲ stages (OR=3.497, P=0.001).ConclusionsADC value of primary tumor is correlated with 2017 staging system of nasopharyngeal carcinoma in China. Clinical stage is a prognostic factor for disease progression.

    网友评论
    网友评论
    分享到微博
    发 布
    参考文献
    引证文献
引用本文

芮银芳,周楠,杨阳,周正扬.扩散加权成像和临床分期在鼻咽癌预后评估中的价值[J].中国耳鼻咽喉颅底外科杂志,2022,28(5):39-44

复制
分享
文章指标
  • 点击次数:644
  • 下载次数: 270
历史
  • 收稿日期:2021-10-13
  • 在线发布日期: 2022-11-01
温馨提示

本刊唯一投稿网址:www.xyosbs.com
唯一办公邮箱:xyent@126.com
编辑部联系电话:0731-84327210,84327469
本刊从未委托任何单位、个人及其他网站代理征稿及办理其他业务联系,谨防上当受骗!

关闭